Can You Believe Botox JUST Got FDA-Approval For This?

Global pharmaceutical giant Allergan recently announced the FDA-approval of Botox for its third indication: the temporary improvement in the appearance of….

Moderate to Severe Forehead Lines.

Whoa!

This recent development makes Botox the first and only neurotoxin that the United State’s government has approved to specifically treat three facial treatment areas: Crow’s Feet, Forehead Lines, and Glabellar lines (the lines in-between your eyebrows).

“Allergan recognizes that forehead lines are a top area of concern for patients,” says David Nicholson, chief research and development officer at Allergan. (Really?!)

Since it’s initial FDA approval in 2002, Botox Cosmetic has been the leading neurotoxin brand for aesthetic-indications in the United States. (In fact, the brand is so recognizable that most people use the word “Botox” to describe any kind of cosmetic injection, much the same way that Band-Aid is used to represent any kind of bandage, and Kleenex is used to reference all kinds of tissue.

“Few products have the level of impact that Botox has had on the medical facial aesthetics industry,” said David Moatazedi, senior vice president, U.S. medical-aesthetics at Allergan. “Botox is the brand that created a new category in facial aesthetics with its first FDA approval 15 years ago. Since then it has continued to be the leading neurotoxin treatment and the world’s number one selling product of its kind,” he explains.

We would show you how surprised we were to hear the news that Botox received approval for the treatment of forehead lines… except we’ve already been doing this treatment for YEARS and you really couldn’t tell our super-surprised faces from our mildly-interested faces.

Since this treatment area is now OFFICIALLY legit, get ready for an avalanche of before + after pictures as all of the offices who have been doing these treatments for years can now safely broadcast their glorious results. (Like this! #humblebrag)

botox forehead instagram 10 20 17